RS-2022-00166539

Development of HER2-positive cancer treatment candidate through interferon-beta immunocytokine efficacy evaluation and production process research

Genopharm, Inc.

ONCOLOGY | **Candidate**

Product Type	Antibody cytokine fusion protein
Indication	HER2-positive solid cancer(breast, stomach, lung), Enhertu-resistant cancer
Target	HER2
MoA(Mechanism of Action)	1) Cancer cell killing through Type I IFN receptor signaling 2) Immune cell-mediated cytotoxicity of tumor cells
Competitiveness	1) GNP101, IFN-beta immunocytokine, induces cancer cell killing through Type I IFN receptor, and shows potency 10 ~ 100 times higher than those of ADC-type drugs such as Kadcyla and Enhertu. 2) Because the mechanism of action of GNP101 is different from that of therapeutic antibodies or ADCs, it is expected that GNP101 would be effective against tumors that have developed resistance to existing drugs.
Development Stage	Candidate
Route of Administration	I.V. (not confirmed)

kddf_bd@kddf.org
KDDF Business Development Team

KDDF Korea Drug Development Fund